SRX Global Inc. Announces Secured Financing with CERo Therapeutics

What Happened
SRX Global Inc. announced it completed a secured financing transaction with CERo Therapeutics Holdings, Inc. (CERO). On August 27, 2026 CERO issued a Consolidated Senior Secured Promissory Note to SRX that consolidates prior CERO promissory notes totaling $5,666,108.77. SRX made an initial advance of $775,665 on the note and may provide additional advances up to $6,000,000 (inclusive of the initial advance), for a maximum aggregate loan of $11,666,108.77. The loan bears interest at 10% per year (with higher default rates), matures October 15, 2026 (subject to limited short extensions), and is secured by CERO’s subsidiary stock and substantially all of the subsidiary’s assets, including IP related to CER-T cell therapy (including CER-1236).

Key Details

• Consolidation amount: $5,666,108.77 of previous notes rolled into one Consolidated Senior Secured Promissory Note.
• Maximum financing capacity: up to $11,666,108.77 total (initial consolidated amount plus up to $6,000,000 additional advances).
• Initial funding: SRX advanced $775,665 on August 27, 2026.
• Terms: 10% annual interest (default rate is the lesser of 24.99% or legal maximum); maturity October 15, 2026; SRX may extend maturity up to four consecutive 30-day periods if no default.
• Security and guaranty: SRX holds a first-priority pledge of the subsidiary’s stock, a security interest in substantially all subsidiary assets (including IP, patents, clinical trials and regulatory filings relating to CER-T therapy/CER-1236), and a guaranty of payment from the subsidiary.
• The note was issued in a private placement relying on Securities Act exemptions (Section 4(a)(2) and Rule 506(b)).

Why It Matters
This is a short-term, secured loan from SRX to CERO that both repays and consolidates prior CERO obligations and gives SRX a secured position in CERO’s subsidiary and key assets. For SRX investors, the arrangement increases the company’s exposure to CERO’s CER-T assets (including potentially valuable intellectual property) while creating near-term credit risk tied to CERO’s ability to repay by the October 15, 2026 maturity (or through permitted short extensions). The 10% interest rate and collateral position are material facts for assessing the financial and strategic implications of SRX’s lending arrangement.